1.
Arber
DA
,
Orazi
A
,
Hasserjian
R
,
Thiele
J
,
Borowitz
MJ
,
Le Beau
MM
, et al.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
.
Blood
.
2016
May
;
127
(
20
):
2391
405
.
[PubMed]
0006-4971
2.
Yogarajah
M
,
Tefferi
A
.
Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome
.
Mayo Clin Proc
.
2017
Jul
;
92
(
7
):
1118
28
.
[PubMed]
0025-6196
3.
Tefferi
A
,
Mudireddy
M
,
Mannelli
F
,
Begna
KH
,
Patnaik
MM
,
Hanson
CA
, et al.
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
.
Leukemia
.
2018
May
;
32
(
5
):
1200
10
.
[PubMed]
0887-6924
4.
Lancman
G
,
Brunner
A
,
Hoffman
R
,
Mascarenhas
J
,
Hobbs
G
.
Outcomes and predictors of survival in blast phase myeloproliferative neoplasms
.
Leuk Res
.
2018
May
;
70
:
49
55
.
[PubMed]
0145-2126
5.
Mollard
LM
,
Chauveau
A
,
Boyer-Perrard
F
,
Douet-Guilbert
N
,
Houot
R
,
Quintin-Roué
I
, et al.
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
.
Leuk Lymphoma
.
2018
Apr
;
•••
:
1
9
.
[PubMed]
1042-8194
6.
Khan
M
,
Siddiqi
R
,
Gangat
N
.
Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms
.
Leuk Res
.
2017
Dec
;
63
:
78
84
.
[PubMed]
0145-2126
7.
Thepot
S
,
Itzykson
R
,
Seegers
V
,
Raffoux
E
,
Quesnel
B
,
Chait
Y
, et al.;
Groupe Francophone des Myelodysplasies (GFM)
.
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
.
Blood
.
2010
Nov
;
116
(
19
):
3735
42
.
[PubMed]
0006-4971
8.
Andriani
A
,
Montanaro
M
,
Voso
MT
,
Villivà
N
,
Ciccone
F
,
Andrizzi
C
, et al.
Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN
.
Leuk Res
.
2015
Aug
;
39
(
8
):
801
4
.
[PubMed]
0145-2126
9.
Badar
T
,
Kantarjian
HM
,
Ravandi
F
,
Jabbour
E
,
Borthakur
G
,
Cortes
JE
, et al.
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
.
Leuk Res
.
2015
Sep
;
39
(
9
):
950
6
.
[PubMed]
0145-2126
10.
Mascarenhas
J
,
Navada
S
,
Malone
A
,
Rodriguez
A
,
Najfeld
V
,
Hoffman
R
.
Therapeutic options for patients with myelofibrosis in blast phase
.
Leuk Res
.
2010
Sep
;
34
(
9
):
1246
9
.
[PubMed]
0145-2126
11.
Niscola
P
,
Abruzzese
E
,
Trawinska
MM
,
Palombi
M
,
Tendas
A
,
Giovannini
M
, et al.
Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation
.
Acta Oncol
.
2017
Oct
;
56
(
10
):
1331
3
.
[PubMed]
0284-186X
12.
Döhner
H
,
Estey
E
,
Grimwade
D
,
Amadori
S
,
Appelbaum
FR
,
Büchner
T
, et al.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
.
Blood
.
2017
Jan
;
129
(
4
):
424
47
.
[PubMed]
0006-4971
13.
Gur
HD
,
Loghavi
S
,
Garcia-Manero
G
,
Routbort
M
,
Kanagal-Shamanna
R
,
Quesada
A
, et al.
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations
.
Am J Surg Pathol
.
2018
Jun
;
42
(
6
):
799
806
. ;
Epub ahead of print
.
[PubMed]
0147-5185
14.
Geissler
K
,
Jäger
E
,
Barna
A
,
Sliwa
T
,
Knöbl
P
,
Schwarzinger
I
, et al.
In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia
.
Eur J Haematol
.
2016
Dec
;
97
(
6
):
562
7
.
[PubMed]
0902-4441
15.
Santini
V
,
Allione
B
,
Zini
G
,
Gioia
D
,
Lunghi
M
,
Poloni
A
, et al.
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
.
Leukemia
.
2018
Feb
;
32
(
2
):
413
8
.
[PubMed]
0887-6924
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.